With a massive influx of new funding, Frederick pharmaceutical company Vaccinogen Inc. is preparing to make big moves that leaders hope will put it on the map.
Vaccinogen announced Aug. 25 it had secured $80 million in funding from Stockholm investors and closed the first $10 million tranche of the funding. The funding will support late-stage clinical studies needed to make Vaccinogen’s OncoVAX commercially available. The drug is designed to reduce recurrence of colon cancer.
{iframe}http://www.bizjournals.com/baltimore/news/2014/08/26/frederick-pharmaceutical-company-plans-move-to.html{/iframe}